Acute Myeloid Leukemia – Landscape & Forecast – Disease Landscape & Forecast

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Historically, it has had a relatively poor prognosis, including low five-year overall survival rates. Chemotherapy backbones have long dominated the treatment of AML, but recent drug approvals suggest a shift toward targeted agents. The approval of Rigel Pharmaceuticals’ Rezlidhia, a potent inhibitor of IDH1, underlines this trend. Rezlidhia joins Tibsovo (ivosidenib) in treating the IDH1-mutated relapsed/refractory AML population. In addition, the early- and late-phase AML pipelines are active and span several drug classes, including kinase inhibitors, radio-immunotherapeutics, menin inhibitors, therapeutic vaccines, antibody-drug conjugates, and CAR T-cell therapies. With the uptake of new therapies and label expansions, we expect the AML therapy market to grow substantially over the 10-year forecast period.

Questions answered:

  • What is the size of the clinically and commercially relevant drug-treatable AML population, and how will drug-treatment rates change over the 2022-2032 forecast period?
  • What is the current treatment landscape for AML? What insights do interviewed experts provide?
  • Which emerging therapies are the most promising for AML? Which drug-treatable subpopulations will they target?
  • What factors are driving the growth of the AML therapy market, and how will this market evolve over the forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancements

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Geographies: United States, EU5, Japan.

Primary research: 19 country-specific interviews with thought-leading hematologist-oncologists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed incidence cases of AML by country, clinically, and market-relevant drug-treatable populations.

Forecast: 10-year, annualized, drug-level, and regimen-level sales and patient share of key AML therapies through 2032, segmented by brands / generics / biosimilars and drug-treatable subpopulations.

Emerging therapies: Phase 2/3: 9+ drugs; coverage of select early-phase products.

Table of contents

  • Acute Myeloid Leukemia - Landscape & Forecast - Disease Landscape & Forecast
    • Key Findings
      • Acute myeloid leukemia - key findings - August 2023
    • Key Updates
      • August 2023
      • April 2023
      • January 2023
      • Q4 2022
        • December 2022
        • October 2022
    • Market Outlook
      • Key findings
        • Market share of drug classes for AML: 2022
        • Market share of drug classes for AML: 2032
        • Drug-treatable population share and major-market sales share in AML: 2022
        • Drug-treatable population share and major-market sales share in AML: 2032
        • Major-market sales of key agents in AML (venetoclax, FLT3 inhibitors, IDH inhibitors, and hypomethylating agents): 2022-2032
        • Major-market sales of key agents in AML (excluding venetoclax, FLT3 inhibitors, IDH inhibitors, and hypomethylating agents): 2022-2032
        • Population positioning of current therapies in AML
        • Population positioning of emerging therapies in AML
        • AML SWOT analysis
      • Market drivers and constraints
        • What factors are driving the market for AML?
        • What factors are constraining the market for AML?
      • Segment-specific trends
        • Patient-share dynamics of key regimens for first-line younger AML patients (aged < 60), United States: 2022-2032
        • Patient-share dynamics of key regimens in first-line AML patients (aged u2265 60), United States: 2022-2032
        • Patient-share dynamics of key regimens in second-line younger AML patients (aged < 60), United States: 2022-2032
        • Patient-share dynamics of key regimens in second-line older AML patients (aged u2265 60), United States: 2022-2032
        • Patient-share dynamics of key regimens in third-line AML, United States: 2022-2032
    • Forecast
      • Market forecast downloads
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease overview
        • Etiology
          • Risk factors associated with AML
        • Disease pathophysiology
          • Select molecular mutations in AML
        • Staging systems in AML
          • FAB classification system
          • 2022 WHO classification of AML and related neoplasms
        • Risk stratification in AML
          • NCCN and ELN risk stratification systems for AML
        • Key pathways and drug targets
          • Select pathways and drug targets
      • Epidemiology
        • Key findings
          • Epidemiology populations
            • Disease definition, methods, and sources used
            • Diagnosed incident cases of acute myeloid leukemia: 2022-2032
            • Acute myeloid leukemia patient flow
            • Drug-treatable cases of acute myeloid leukemia: 2022-2032
            • Drug-treated cases of acute myeloid leukemia: 2022-2032
        • Current Treatment
          • Key findings
            • Treatment goals
              • Key endpoints used in clinical trials for AML
            • Key current therapies
              • Overview
              • Mechanism of action of key current drugs used for AML
              • Current treatments used for AML
              • Market events impacting the use of key current therapies for AML
              • Key results from select clinical trials investigating injectable azacitidine for the treatment of AML
              • Expert insight: injectable azacitidine
              • Key results from select clinical trials investigating Onureg (oral azacitidine) for the treatment of AML
              • Ongoing clinical development of Onureg (oral azacitidine)
              • Key ongoing clinical trials of Onureg (oral azacitidine) in the treatment of AML
              • Expert insight: Onureg (oral azacitidine)
              • Key results from select clinical trials investigating decitabine for the treatment of AML
              • Key results from select clinical trials investigating Mylotarg for the treatment of AML
              • Ongoing clinical development of Mylotarg
              • Key ongoing clinical trials of Mylotarg in the treatment of AML
              • Expert insight: Mylotarg
              • Key results from select clinical trials investigating Rydapt for the treatment of AML
              • Ongoing clinical development of Rydapt
              • Key ongoing clinical trials of Rydapt in the treatment of AML
              • Expert insight: Rydapt
              • Key results from select clinical trials investigating Xospata for the treatment of AML
              • Ongoing clinical development of Xospata
              • Key ongoing clinical trials of Xospata in the treatment of AML
              • Expert insight: Xospata
              • Key results from select clinical trials investigating Vanflyta for the treatment of AML
              • Ongoing clinical development of Vanflyta
              • Key ongoing clinical trials of Vanflyta in the treatment of AML
              • Expert insight: Vanflyta
              • Key results from select clinical trials investigating Vyxeos for the treatment of AML
              • Ongoing clinical development of Vyxeos
              • Key ongoing clinical trials of Vyxeos in the treatment of AML
              • Expert insight: Vyxeos
              • Key results from select clinical trials investigating Idhifa for the treatment of AML
              • Ongoing clinical development of Idhifa
              • Key ongoing clinical trials of Idhifa in the treatment of AML
              • Expert insight: Idhifa
              • Key results from select clinical trials investigating Tibsovo for the treatment of AML
              • Ongoing clinical development of Tibsovo
              • Key ongoing clinical trials of Tibsovo in the treatment of AML
              • Expert insight: Tibsovo
              • Key results from select clinical trials investigating Rezlidhia for the treatment of AML
              • Analysis of the clinical development program for Rezlidhia
              • Key results from select clinical trials investigating Venclexta / Venclyxto for the treatment of AML
              • Ongoing clinical development of Venclexta / Venclyxto
              • Key ongoing clinical trials of Venclexta / Venclyxto in the treatment of AML
              • Expert insight: Venclexta / Venclyxto
              • Key results from select clinical trials investigating Daurismo for the treatment of AML
              • Ongoing clinical development for Daurismo
              • Key ongoing clinical trials of Daurismo in the treatment of AML
              • Expert insight: Daurismo
            • Medical practice
              • First-line AML, younger patients (aged < 60)
              • First-line AML, older patients (aged u2265 60)
              • Relapsed / refractory AML
              • Patient characteristics influencing drug selection in AML
              • Treatment decision tree for acute myeloid leukemia: United States
              • Treatment decision tree for acute myeloid leukemia: Europe
              • Treatment decision tree for acute myeloid leukemia: Japan
          • Unmet Need Overview
            • Current and future attainment of unmet needs in AML
            • Top unmet needs in acute myeloid leukemia: current and future attainment
          • Drug Pipeline
            • Pipeline
            • Regulatory Milestones
            • Indication Comparison
          • Emerging Therapies
            • Key findings
              • Key emerging therapies
                • Key therapies in development for AML
                • Estimated market authorization dates of key emerging therapies for the treatment of AML
                • Key results from select clinical trials investigating crenolanib for the treatment of AML
                • Analysis of the clinical development program for crenolanib
                • Key ongoing clinical trials of crenolanib in the treatment of AML
                • Expert insight: crenolanib
                • Expectations for market authorization and sales opportunity of crenolanib in AML
                • Key results from select clinical trials investigating uproleselan for the treatment of AML
                • Analysis of the clinical development program for uproleselan
                • Key ongoing clinical trials of uproleselan in the treatment of AML
                • Expert insight: uproleselan
                • Expectations for market authorization and sales opportunity of uproleselan for AML
                • Key results from select clinical trials investigating revumenib for the treatment of AML
                • Analysis of the clinical development program for revumenib
                • Key ongoing clinical trials of revumenib in the treatment of AML
                • Expert insight: revumenib
                • Expectations for market authorization and sales opportunity of revumenib for AML
                • Key results from select clinical trials investigating ziftomenib for the treatment of AML
                • Analysis of the clinical development program for ziftomenib
                • Key ongoing clinical trials of ziftomenib in the treatment of AML
                • Expert insight: ziftomenib
                • Expectations for market authorization and sales opportunity of ziftomenib for AML
                • Key results from select clinical trials investigating Inqovi for the treatment of AML
                • Analysis of the clinical development program for Inqovi
                • Expert insight: Inqovi
                • Expectations for market authorization and sales opportunity of Inqovi in AML
                • Key results from select clinical trials investigating radgocitabine for the treatment of AML
                • Analysis of the clinical development program for radgocitabine
                • Key ongoing clinical trials of radgocitabine in the treatment of AML
                • Expert insight: radgocitabine
                • Expectations for market authorization and sales opportunity of radgocitabine in AML
                • Key results from select clinical trials investigating magrolimab for the treatment of AML
                • Analysis of the clinical development program for magrolimab
                • Key ongoing clinical trials of magrolimab in the treatment of AML
                • Expert insights: magrolimab
                • Expectations for market authorization and sales opportunity of magrolimab in AML
                • Key results from select clinical trials investigating OmnImmune for the treatment of AML
                • Analysis of the clinical development program for OmnImmune
                • Key ongoing clinical trials of OmnImmune in the treatment of AML
                • Expectations for market authorization and sales opportunity of OmnImmune in AML
                • Key results from select clinical trials investigating Iomab-B for the treatment of AML
                • Analysis of the clinical development program for Iomab-B
                • Expert insight: Iomab-B
                • Expectations for market authorization and sales opportunity of Iomab-B in AML
                • Mocravimod
                • Key results from select clinical trials investigating mocravimod for the treatment of AML
                • Analysis of the clinical development program for mocravimod
                • Key ongoing clinical trials of mocravimod in the treatment of AML
                • Expectations for market authorization and sales opportunity of mocravimod for AML
              • Early-phase pipeline analysis
                • Select compounds in early-phase development for AML
            • Access & Reimbursement Overview
              • Region-specific reimbursement practices
                • Key market access considerations in AML: United States
                • General reimbursement environment: United States
                • Key market access considerations in AML: EU5
                • General Reimbursement Environment: EU5
                • Key market access considerations in AML: Japan
                • General reimbursement environment: Japan
            • Appendix
              • Abbreviation table
              • Acute myeloid leukemia bibliography

          Login to access report